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Inhibition of Hemangiogenesis and Lymphangiogenesis
after Normal-Risk Corneal Transplantation by
Neutralizing VEGF Promotes Graft Survival
Claus Cursiefen,1,2,3 Jingtai Cao,4 Lu Chen,1 Ying Liu,1 Kazuichi Maruyama,1
David Jackson,5 Friedrich E. Kruse,3 Stanley J. Wiegand,4 M. Reza Dana,1 and
J. Wayne Streilein1,6
PURPOSE. To evaluate the occurrence and time course of hem-
and lymphangiogenesis after normal-risk corneal transplanta-
tion in the mouse model and to test whether pharmacologic
strategies inhibiting both processes improve long-term graft
survival.
METHODS. Normal-risk allogeneic (C57BL/6 to BALB/c) and syn-
geneic (BALB/c to BALB/c) corneal transplantations were per-
formed and occurrence and time course of hem- and lymph-
angiogenesis after keratoplasty was observed, by using double
immunofluorescence of corneal flatmounts (with CD31 as a
panendothelial and LYVE-1 as a lymphatic vascular endo-
thelium–specific marker). A molecular trap designed to elimi-
nate VEGF-A (VEGF TrapR1R2; 12.5 mg/kg) was tested for its
ability to inhibit both processes after keratoplasty and to pro-
mote long-term graft survival (intraperitoneal injections on the
day of surgery and 3, 7, and 14 days later).
RESULTS. No blood or lymph vessels were detectable immedi-
ately after normal-risk transplantation in either donor or host
cornea, but hem- and lymphangiogenesis were clearly visible at
day 3 after transplantation. Both vessel types reached donor
tissue at 1 week after allografting and similarly after syngeneic
grafting. Early postoperative trapping of VEGF-A significantly
reduced both hem- and lymphangiogenesis and significantly
improved long-term graft survival (78% vs. 40%; P  0.05).
CONCLUSIONS. There is concurrent, VEGF-A-dependent hem- and
lymphangiogenesis after normal-risk keratoplasty within the
preoperatively avascular recipient bed. Inhibition of hem- and
lymphangiogenesis (afferent and efferent arm of an immune
response) after normal-risk corneal transplantation improves
long-term graft survival, establishing early postoperative hem-
and lymphangiogenesis as novel risk factors for graft rejection
even in low-risk eyes. (Invest Ophthalmol Vis Sci. 2004;45:
2666–2673) DOI:10.1167/iovs.03-1380
Corneal transplantation is the oldest, most successful, andmost commonly performed tissue transplantation, with
nearly 40,000 transplantations a year alone in the United
States.1 When corneal grafts are placed into an avascular recip-
ient bed (so-called normal-risk keratoplasty), 2-year graft sur-
vival rates approach 90% under cover of topical steroids, even
without HLA-matching.2 This very successful outcome is attrib-
utable to corneal immune privilege (i.e., the phenomenon of
suppressed corneal inflammation induced by an array of en-
dogenous mechanisms that downregulate alloimmune and in-
flammatory responses in the cornea and its bed). These mech-
anisms include the lack of both afferent lymphatic and efferent
blood vessels in the normal-risk recipient cornea, lack of MHC
II antigen-presenting cells (APCs), FASL-expression on cor-
neal epithelium and endothelium, and the anterior chamber
associated immune privilege (ACAID) directed at graft anti-
gens, for example (for review see Ref. 1). In contrast, survival
rates of corneal grafts placed into vascularized, not immune-
privileged recipient beds (so called high-risk keratoplasty) de-
crease significantly to below 50% (even with local and systemic
immune suppression).3,4 Preexisting corneal stromal blood
vessels have been identified as strong risk factors for immune
rejection after corneal transplantation, both in the clinical
setting4 and in the well-defined mouse model of corneal trans-
plantation.5 Recently, in addition to blood vessels, biomicro-
scopically undetectable lymphatic vessels have been found in
association with blood vessels in vascularized high-risk human
corneas,6,7 and it is likely that corneal lymphatic vessels enable
effective access of donor and host APCs and antigenic material
to regional lymph nodes where accelerated sensitization to
graft antigens occurs.8
But even in the normal-risk setting (with a preoperatively
avascular recipient bed), mild corneal hemangiogenesis devel-
ops after keratoplasty9–11: Outgrowth of new blood vessels
from the limbal arcade toward the graft can be observed within
the first postoperative year in approximately 50% of patients
undergoing normal-risk keratoplasty, and in 10% of patients
these new blood vessels even reach the interface or invade
donor tissue11 at corneal suture sites and then proceed cen-
trally.9–11
Both hem- and lymphangiogenesis (i.e., the outgrowth of
new blood vessels versus lymphatic vessels from preexisting
vessels) are mediated by members of the VEGF growth factor
family: VEGF (VEGF-A) induces hem- and lymphangiogenesis
by binding to VEGF receptor (VEGFR)-1 and -2. VEGF-B reacts
only with VEGFR1. The lymphangiogenic molecules VEGF-C
and VEGF-D both bind to VEGFR2 and VEGFR3 (for review see
Ref. 12). In tumor hemangiogenesis as well as in other condi-
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tions of hypoxic and inflammatory hemangiogenesis, VEGF-A
through VEGFR2-ligation has emerged as the main growth
factor that induces hemangiogenesis.12
Using the mouse model of normal-risk keratoplasty, the
present study analyzed (1) whether lymphangiogenesis accom-
panies hemangiogenesis after normal-risk keratoplasty, (2) the
time course of blood and lymphatic vessel outgrowth after
keratoplasty, (3) whether there is a difference in postkerato-
plasty angiogenesis between syngeneic and allogeneic grafting,
and (4) whether inhibition of hem- and lymphangiogenesis by
a molecular trap designed to eliminate VEGF-A (VEGF
TrapR1R2) promotes long-term graft survival in the normal-risk
keratoplasty setting.
METHODS
Mice and Anesthesia
Six- to 8-week-old male C57BL/6 mice were used as donors, and
same-aged male BALB/c mice (Taconic, Germantown, NY) as recipi-
ents in the mouse model of normal-risk keratoplasty.13 For syngeneic
transplantations, 6- to 8-week-old male BALB/c mice were used both as
donors and as recipients. For the dose–response studies, 8-week-old
male C57BL/6 mice were used. All animals were treated in accordance
with the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. Mice were anesthetized using a mixture of ketamine
and xylazine (120 mg/kg and 20 mg/kg body weight, respectively).
Dose–Response of VEGF TrapR1R2
To establish the minimum dose of VEGF TrapR1R2, a molecular trap for
VEGF-A (described later), that would effectively suppress corneal neo-
vascularization for at least 1 week, five different doses of VEGF
TrapR1R2 were tested in mice, which received three interrupted intra-
stromal sutures (10-0 nylon, 50 m-diameter; Sharpoint, Surgical Spe-
cialties Corp., Reading, PA; n  5 mice per dosage). Gentamicin and
ophthalmic ointment were applied immediately after surgery. After
surgery (day 0), mice received a single subcutaneous injection of VEGF
TrapR1R2 (25, 12.5, 6.25, 2.5 or 0.5 mg/kg) or human Fc (12.5 mg/kg;
control). Corneas were harvested on day 9 after suture placement, after
an intravenous administration of an endothelium-specific fluorescein-
conjugated lectin (Lycopersicon esculentum; Vector Laboratories, Bur-
lingame, CA). The isolated corneas were flatmounted on glass slides,
and images of lectin-labeled vessels were captured with a digital cam-
era (Spot RT; Diagnostic Instruments, Inc., Sterling Heights, MI) at-
tached to a microscope (Microphot-FXA; Nikon Inc., Garden City, NY).
Image-analysis software (Image 1.62c; Scion Corporation, Frederick,
MD) was used to quantify the extent of corneal neovascularization.
Corneal Transplantation in Mice
Orthotopic corneal allografting in the mouse model of normal-risk
keratoplasty was performed as described previously.13 Donor corneas
were excised by trephination using a 2.0 mm bore and cut with curved
Vannas scissors. Until grafting, corneal tissue was placed in chilled
phosphate-buffered saline (PBS). Recipients were anesthetized, and the
graft bed was prepared by trephining a 1.5-mm site in the central
cornea of the right eye and discarding the excised cornea. The donor
cornea was immediately applied to the bed and secured in place with
eight interrupted sutures (11-0 nylon, 70-m diameter needles; Arosur-
gical, Newport Beach, CA). Antibiotic ointment (Oxymycin; Pharma-
fair, Hauppauge, NY) was placed on the corneal surface and the eyelids
sutured with 8-0 suture (Sharpoint; Surgical Specialties Corp.). Recip-
ients of grafts in which bleeding developed in the immediate postop-
erative period were discarded from further evaluation. All grafted eyes
were examined after 72 hours, and grafts with technical difficulties
(hyphema, cataract, infection, loss of anterior chamber) were excluded
from further consideration. Tarsorrhaphy and corneal sutures were
removed after 7 days, and grafts were then examined at least twice a
week until week 8 after transplantation by slit lamp microscopy and
scored for opacity as described previously.13 The survival experiment
was performed twice and comprised 10 and 12 mice per experiment
in both groups. Clinical scores of corneal grafts for opacity were as
follows: 0, clear; 1, minimal, superficial (nonstromal) opacity; pupil
margin and iris vessels readily visible through the cornea;2, minimal,
deep (stromal) opacity; pupil margins and iris vessels visible; 3,
moderate stromal opacity; only pupil margin visible; 4, intense stro-
mal opacity; only a portion of pupil margin visible; and 5, maximum
stromal opacity; anterior chamber not visible. Grafts with opacity
scores of 2 or greater after 2 weeks were considered to have been
rejected.13 Syngeneic transplantations were performed and evaluated
in a similar manner.
Immunohistochemistry and Morphometry of
Angiogenesis and Lymphangiogenesis
in the Cornea
Briefly, corneal flatmounts were rinsed in PBS, fixed in acetone,
rinsed in PBS, blocked in 2% bovine serum albumin, stained with
FITC-conjugated CD31/platelet–endothelial cell adhesion molecule
(PECAM)-1 overnight (1:100; Santa Cruz Biotechnology, Santa Cruz,
CA), washed, blocked, stained with LYVE-1 (1:500; a lymphatic endo-
thelium-specific hyaluronic acid receptor),6,14 washed, blocked, and
stained with Cy3 (1:100; Jackson ImmunoResearch Laboratories, West
Grove, PA), and analyzed by microscope (Axiophot; Carl Zeiss Med-
itec). Digital pictures of the flatmounts were taken with an image-
analysis system (Spot; Diagnostic Instruments). Then, the area covered
by CD313/LYVE-1 blood vessels and CD31/LYVE-13 lymph ves-
sels6 was measured morphometrically on the flatmounts with NIH
Image software (available by ftp at zippy.nimh.nih.gov/ or at http://
rsb.info.nih.gov/nih-image; developed by Wayne Rasband, National
Institutes of Health, Bethesda, MD). The total corneal area was out-
lined, with the innermost vessel of the limbal arcade serving as the
border. The total area of blood versus lymphatic neovascularization
was then normalized to the total corneal area and the percentage of the
cornea covered by each vessel type calculated.
Neutralization of VEGF-A with a Cytokine Trap:
VEGF TrapR1R2
A newly designed molecular trap for VEGF-A, VEGF TrapR1R2, compris-
ing the receptor binding domains of VEGF receptor 1 and 2 coupled to
a human Fc fragment (Regeneron Pharmaceuticals Inc., Tarrytown,
NY)15 was used in the transplant survival experiment at a concentra-
tion of 12.5 mg/kg intraperitoneally (IP) at time of surgery (CHO
hVEGFR1 [Ig domain 2], R2 [Ig domain 3]-Fc), and 3, 7, and 14 days
after surgery.15 Human Fc-fragment given IP at same concentration and
times was used in the control mice (sCHO h Fc).
Statistical Analysis
Statistical significance was analyzed by the Mann-Whitney test. Differ-
ences were considered significant at P  0.05. Each experiment was
performed at least twice with similar results. Graphs were drawn by
computer (Prism, ver. 3.02; Graph Pad, San Diego, CA).
RESULTS
Dose–Response of Angiogenesis Inhibition by
VEGF TrapR1R2
As shown in Figure 1, VEGF TrapR1R2, at doses of 25 or 12.5
mg/kg, completely inhibited suture-induced inflammatory cor-
neal neovascularization. In contrast, doses of 6.25 and 2.5
mg/kg produced 50% and 20% inhibition of corneal neo-
vascularization, respectively, whereas the lowest dose tested,
0.5 mg/kg, had a negligible effect (5% inhibition). Therefore,
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FIGURE 1. Dose–response of the an-
tiangiogenic effect of VEGF TrapR1R2.
Immediately after placement of in-
trastromal corneal sutures, mice re-
ceived human Fc protein (control: A)
or 25 (B), 12.5 (C), 6.25 (D), 2.5 (E),
or 0.5 (F) mg/kg VEGF TrapR1R2. The
dose of 12.5 mg/kg was the lowest
that provided complete inhibition of
suture-induced corneal neovascular-
ization (as measured in lectin-stained
corneal flatmounts 9 days after su-
ture placement; the limbal vascular
arcade is located at the bottom of
each image). Magnification, 100.
FIGURE 2. Early, combined induc-
tion of hem- and lymphangiogenesis
after normal-risk allogeneic kerato-
plasty. There was neither biomicro-
scopically (A) nor immunohistochemi-
cally (B/C: CD31 blood vessels:
green; LYVE-1 lymphatic vessels:
red) detectable hem- or lymphangio-
genesis immediately after normal-risk
allogeneic keratoplasty (B: corneal
flatmount; C: detail from B). By day 3
after surgery (D–F), corneal blood
vessels (Bl) grew into the avascular
recipient beds. Immunostaining re-
vealed new blood vessels to be ac-
companied by lymphatic vessels (E,
F: red vessels). Both vessel types
penetrated approximately 30% to
50% from the limbus to the graft bed.
One week after normal-risk kerato-
plasty (G–I) both vessels types had
already reached donor tissue and
spread along the interface (H, I), but
these vessels rarely invade donor tis-
sue. Li, limbal vascular arcade; IF,
interface.
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for subsequent experiments, a dose of 12.5 mg/kg VEGF
TrapR1R2 was chosen.
Rapid and Parallel Onset of Hemangiogenesis and
Lymphangiogenesis after Normal-Risk Allogeneic
Corneal Transplantation
To determine whether the mild and temporary hemangiogen-
esis occurring after normal-risk keratoplasty is accompanied by
lymphatic vessel outgrowth from the limbus into the normally
alymphatic cornea, we studied the time course of ingrowth of
both vessel types at days 0, 3, 7, 14, 21, and 28 after allogeneic
keratoplasty (only accepted grafts). Immediately after surgery,
blood, and lymphatic vessels were not detectable either in the
host or in donor tissue using biomicroscopy and immunohis-
tochemistry on corneal flatmounts (Fig. 2). But, at day 3 after
allografting, both methods revealed new blood vessels growing
into the cornea already one third to one half the way toward
the graft interface. By day 7, these vessels had usually reached
the donor tissue, but they rarely invaded the donor tissue itself.
Analyzing flatmounts stained with LYVE-1 as a lymphatic ves-
sel–specific marker showed that CD313/LYVE-1 blood ves-
sels were regularly accompanied by LYVE-13/CD31 lym-
phatic vessels (Fig. 2). Both vessel types reached the interface
simultaneously at day 7. Thereafter, coincident with suture
removal, both vessel types started to regress (if no immune
rejection occurred; data not shown).
Difference in Postkeratoplasty Hem- and
Lymphangiogenesis between Syngeneic and
Allogeneic Corneal Transplantation
To determine whether the simultaneous induction of hem- and
lymphangiogenesis after normal-risk keratoplasty is primarily
an effect of the surgical trauma, suturing, and wound-healing
processes or is secondary to early immunologic rejection reac-
tions, we compared the speed and extent of both hem- and
lymphangiogenesis occurring after keratoplasty between allo-
geneic (C57BL/6 into BALB/c) and syngeneic grafts (BALB/c
into BALB/c) at days 3, 7, 14, 21, and 28 after transplantation
(Fig. 3). In both groups, blood and lymphatic vessels grew out
after keratoplasty and by day 3 reached approximately one
third to one half of the limbus–interface distance. At day 7 after
syngeneic and allogeneic grafting, both vessel types had
reached the interface, before they started to regress. Further-
more, there was no significant difference in the hem- and
FIGURE 3. Combined induction of
hem- and lymphangiogenesis after al-
logeneic and syngeneic keratoplasty.
Allogeneic cornea grafts (A, C:
C57BL/6 to BALB/c) and syngeneic
corneal grafts (B, D: BALB/c to
BALB/c) were compared. The micro-
graphs depict representative seg-
ments from corneal flatmounts at
days 3 (A, B) and 7 (C, D) after graft-
ing. The limbal vascular arcade (Li) is
at the left; the graft-bed-interface (IF)
is at the right. (E) Morphometric
comparison reveals no significant dif-
ferences between allo- and syngeneic
grafting with respect to hem- and
lymphangiogenesis (either at day 3
[shown] or at day 7 [not shown]; n
8 mice per group).
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lymphovascularized area, comparing syngeneic and allogeneic
grafts at 3 days (allogeneic with hemovascularized area [HA]
25.2%  4.1% and lymphovascularized area [LA] 22.2%  9.4%
vs. syngeneic HA: 23%  2.7% and LA 19.4%  7.2%) and 7
days (allogeneic HA: 53.8%  11.2% and LA: 37.9%  6.2% vs.
syngeneic HA: 55.9%  8.2% and LA: 38%  22.7%) after
surgery (n  8 mice per group per time point).
Effect of Neutralization of VEGF-A after Normal-
Risk Keratoplasty on Postoperative
Hemangiogenesis and Lymphangiogenesis
To determine the extent to which combined hem- and lym-
phangiogenesis occurring after keratoplasty depends on
VEGF-A, we analyzed the effect of pharmacological neutraliza-
tion of VEGF-A using a novel cytokine trap (VEGF
TrapR1R2).
15,16 Mice received either intraperitoneal injections
of VEGF TrapR1R2 (12.5 mg/kg) at surgery and 3 days later.
Control animals received the Fc-protein in the same dosage. At
day 3 and 7 after surgery, the extent of hem- and lymphangio-
genesis was compared between these two groups (n  6 mice
per group per time point). At days 3 and 7 after surgery, the
hemovascularized area was significantly smaller in trap-treated
mice (day 3: 15.8%  4.0%; day 7: 25.2%  13.3%) compared
with mice receiving only the Fc-fragment (day 3: 25.8% 
4.4%; day 7: 48.3%  12.8%; P  0.0001; Fig. 4). This was also
true of the lymphovascularized area comparing Trap- (9.5 
9.4%) and Fc-treated mice on day 3 (21.5%  9.3%; P 
0.0001). At day 7, the lymphovascularized area was smaller,
but not significantly different in the Trap-group (28.7% 
20.3%) compared with the Fc-group (51.5%  23.8%; P 
0.06). In contrast to results obtained in corneal injury models
(Cao et al., manuscript submitted)16 neither hem- or lymph-
angiogenesis was completely inhibited by the VEGF TrapR1R2
after corneal transplantation. However, the number of
lymphatic vessels reaching the graft–host interface (10.6 0.6
vs. 1.3  1.5 vessels) and the number of hours that the
interface was filled with draining lymphatic vessels were much
more in the Fc-treated than in the Trap-treated group at day 7
(3  2 vs. 0.2  0.3 hours; not significant due to small sample
size). This may indicate that lymphovascularized area per se is
less decisive for host sensitization than the contact area with
donor tissue (described later).
Effect on Graft Survival of Partial Inhibition of
Early Postoperative Hem- and
Lymphangiogenesis by Trapping VEGF-A after
Normal-Risk Surgery
Because hem- and lymphangiogenesis that occurred after nor-
mal-risk keratoplasty peaked around day 7, and regressed there-
after, and because both vascular processes could be signifi-
cantly inhibited by early postoperative neutralization of
FIGURE 4. Effect of pharmacologic
neutralization of VEGF-A on hem- and
lymphangiogenesis after normal-risk
allogeneic keratoplasty. Compared
with the Fc-treated control (A),
VEGF-A neutralization using VEGF
TrapR1R2 (B) inhibited both clinically
visible hemangiogenesis (green) as
well as biomicroscopically invisible
LYVE-1 lymphangiogenesis (red;
shown as detail from corneal flat-
mounts; between donor at bottom
and host at top). (C) Morphometry at
day 3 after penetrating keratoplasty
demonstrates significant inhibition of
both hem- and lymphangiogenesis by
VEGF-A neutralization (P  0.001; n
 6 per group). Li, limbus; IF,
interface.
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VEGF-A, we determined whether inhibition of postkeratoplasty
hem- and lymphangiogenesis during this interval improved
graft survival. The long-term survival of C57BL/6 grafts placed
into avascular BALB/c recipient beds was compared between
mice receiving an IP injection of 12.5 mg/kg VEGF TrapR1R2
and those receiving Fc-fragment alone, at surgery and 3, 7, and
14 days later. As Figure 5 shows, trapping of VEGF-A caused
significantly improved long-term graft survival at 8 weeks after
surgery (78%), compared with grafts in eyes of Fc-treated
control mice (40%; P  0.044; n  22 in both groups).
DISCUSSION
Whereas preexisting corneal blood vessels have long been
established as risk factors for immune rejection after corneal
transplantation,4,13 the pathogenesis, potential association
with lymphangiogenesis, and immunologic importance of mild
hemangiogenesis after normal-risk keratoplasty have yet to be
determined.9–11 Using the mouse model of normal-risk kerato-
plasty, we provide novel evidence (1) that normal-risk kerato-
plasty itself promotes parallel and rapid outgrowth of both
blood and lymphatic vessels into the avascular recipient bed;
(2) that because there was no significant difference between
postoperative hem- and lymphangiogenesis comparing synge-
neic and allogeneic corneal grafting, early postoperative re-
lease of hem- and lymphangiogenic growth factors seems to be
triggered mainly by surgical trauma, wound-healing, and cor-
neal suturing rather than immune rejection; (3) that neutraliza-
tion of VEGF-A after surgery not only inhibited hem- and lym-
phangiogenesis, but promoted long-term corneal allograft
survival. The results establish hem- and lymphangiogenesis
occurring after normal-risk keratoplasty as novel risk factors for
subsequent immune rejections.
The molecular trap (VEGF TrapR1R2) used in this study
neutralized VEGF-A and PlGF with high affinity. Neutralization
of VEGF-A has recently been shown to inhibit not only hem-
and lymphangiogenesis, but also to interfere with recruitment
of inflammatory cells into the cornea (Cao J, et al., manuscript
submitted).16 This effect of VEGF neutralization has been at-
tributed to inhibition of neutrophil and macrophage chemo-
taxis mediated by ligation of VEGFR1.17,18 Trapping of VEGF-A
thereby exerts direct and indirect antiangiogenic effects.
Therefore, the graft survival-promoting effect of VEGF-A neu-
tralization can also be attributed to multiple mechanisms. First,
inhibition of hem- and lymphangiogenesis after keratoplasty
interferes with the development of both an afferent (lymphatic
vessels) and an efferent pathway (blood vessels) for a subse-
quent immune response.1,7 In addition, trapping of VEGF-A
may impede the recruitment of APCs to the graft bed.
The relative importance of heme versus lymphangiogenesis
after normal-risk keratoplasty for subsequent immune rejec-
tions remains unknown, because in this study both processes
were equally inhibited by VEGF TrapR1R2. On the one hand,
blood vessels reaching the graft are essential for delivery of
APCs and alloreactive T-lymphocytes to the graft. On the other
hand, lymphatic vessels seem to facilitate escape of APCs to
regional lymph nodes, enhancing allosensitization. However,
studies demonstrating that removal of regional lymph nodes
can promote complete survival of corneal allografts placed in
high- and normal-risk settings,19,20 and a study demonstrating
increased transport of donor APCs to regional lymph nodes in
inflamed (and probably lymphovascularized) beds,8 suggest
that afferent corneal lymphatics that promote sensitization
may be equal, or even more important than efferent corneal
blood vessels that provide an entry route for immune effector
cells.
Corneal allograft survival in the normal-risk mouse model
(C57BL/6 to BALB/c) is reduced from around 50% after 8
weeks to 0% after 2 weeks, if the recipient bed is prevascular-
ized.5,21 We have demonstrated parallel outgrowth of both
blood and lymphatic vessels in this model,16 implying that
donor tissue has immediate access to draining host lymphatic
vessels after high-risk grafting and is exposed to efferent host
blood vessels. Because we demonstrated in the current study
that 1 week after normal-risk keratoplasty both vessels types
also reached donor tissue, the question arises of why the
survival rates between C57BL/6 grafts placed into avascular,
but neovascularizing versus already neovascularized graft beds,
are so different. One explanation concerns the possibility of a
time-dependent window of opportunity during which recipi-
ent sensitization to donor alloantigens after keratoplasty leads
to graft rejection. Whereas grafts placed in high-risk eyes in-
duce donor-specific sensitization promptly (within 7 days),5
presumably because antigens have access to draining lymph
nodes through preestablished lymphatics, by contrast, allo-
grafts placed in low-risk eyes do not generate sensitization until
2 to 4 weeks after grafting,22 probably reflecting the time
needed for lymphangiogenesis to develop. Once the drainage
system is established, graft-derived antigens reach the local
lymph node, and activate donor-specific alloreactive T-cells,
which can cause rejection. If, however, sensitized T cells
disseminate only after 14 to 21 days, these effectors must
compete with the regulatory T-cells of ACAID which begin to
emerge at that time.23 Neutralization of VEGF-A at the time of
surgery retards lymphangiogenesis in the graft bed, thus nar-
rowing the window of opportunity during which recipient
sensitization takes place and therefore may reflect a shift in the
balance of the recipient alloimmune response toward accep-
tance (ACAID) rather than rejection. This idea is compatible
with the observation that a temporary depletion of local mac-
rophages by subconjunctival injection of clodronate liposomes
at the time of keratoplasty in low-risk eyes achieves permanent
survival of most of these grafts.24–25 Other possible explana-
tions include a role for the degree of antigen flow, the APC
phenotype, and other related or unrelated differences between
these graft types.
Inhibition of both hem- and lymphangiogenesis by neutral-
ization of VEGF-A was incomplete in this study of keratoplasty,
whereas the same dosage of VEGF Trap in a previous study
completely inhibited both angiogenic processes after corneal
suturing.16 This may suggest that the release of angiogenic
factors after corneal transplantation is greater than after suture
FIGURE 5. Effect of pharmacologic neutralization of VEGF-A on sur-
vival of allogeneic cornea grafts. Panels of BALB/c mice received
orthotopic transplants from C57BL/6 donors in one low-risk eye. The
recipients in one panel were treated with VEGF TrapR1R2, whereas the
other panel (control) received Fc-fragments only. Survival of grafts in
mice treated with VEGF Trap was significantly greater than in control
animals (78% vs. 40%; P  0.05; n  22 mice in both groups).
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placement alone, and that the present dosing regimen is insuf-
ficient for complete suppression of angiogenesis in this con-
text. Alternatively, because lymphangiogenesis is thought to be
mediated mainly by VEGF-C and -D binding to their high-affinity
receptor VEGFR3 on lymphatic vascular endothelium,12,26–29
and because the VEGF TrapR1R2 used in this study does not
bind VEGF-C and -D,16 adding VEGFR3-signaling inhibitors to
the treatment regimen may more completely inhibit lymph-
angiogenesis and further improve graft survival after normal-
risk keratoplasty. The fact that pharmacological neutralization
of VEGF-A, which is mainly thought of as a hemangiogenic
growth factor,12,26–29 significantly inhibited lymphangiogen-
esis, suggests a novel, important role for VEGF-A in generating
lymphangiogenesis and in promoting sensitization to donor
antigens. In line with this interpretation, an important role for
VEGF-A in another transplant setting was recently demonstrat-
ed.30 For human cardiac allografts a correlation between in-
creased intragraft VEGF-levels, inflammatory cell influx and all
grades of acute rejection was shown.30 It has been reported
that topically applied anti-VEGF antibodies reduced the degree
of inflammation and hemangiogenesis in the rat model of
high-risk keratoplasty (Lewis to Fisher rats),31 and could im-
prove short-term survival of grafts in this high-risk model.31
The occurrence of lymphangiogenesis or the effect of inhibit-
ing hem- and lymphangiogenesis on long-term survival were
not analyzed in this study.31
Our finding that there was no difference in early postop-
erative hem- and lymphangiogenesis after syngeneic versus
allogeneic grafting suggests an important role of surgery and
surgery-related wound healing in inducing these vascular
responses, rather than immunologic mechanisms. This is in
line with a previous study in humans in which the degree of
postkeratoplasty hemangiogenesis was significantly lower in
patients after nonmechanical excimer laser trephination
(which induces less vigorous wound healing) than after
mechanical trephination.9 Taken together, the evidence sug-
gests a novel role of surgery/wound healing itself in deter-
mining the immunologic fate of corneal grafts and a close
association of immune and angiogenic responses in the
cornea.32
Thinking about translating the results obtained in our study
to the clinical setting, one has to keep in mind that important
differences exist between penetrating keratoplasty in humans
and in the mouse model: continuous suturing in human low-
risk patients versus interrupted sutures in mouse surgery, su-
ture placement for over 1 year in patients compared with 1
week in mice and longer distances between interface and
vessels at the limbus in patients compared with mice, for
example. Therefore, because our results establish hem- and
lymphangiogenesis postkeratoplasty as novel risk factors for
subsequent immune rejections even after normal-risk trans-
plantation in the mouse model, it seems reasonable to deter-
mine whether this association also holds true for patients,
whether there is postkeratoplasty lymphangiogenesis in hu-
mans, and when the association is confirmed in patients, to try
to inhibit postkeratoplasty neovascularization and improve
graft survival.
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